Dose of prophylactic platelet transfusions did not affect bleeding incidence or severity

Rabinowitz, Ian
June 2010
ACP Journal Club;6/15/2010, Vol. 152 Issue 6, p11
Academic Journal
The article offers information on the clinical trial conducted on the impact of prophylactic platelet transfusions on bleeding incidence in patients with hypoproliferative thrombocytopenia. The trial studied 1351 patients of different age suffering from hematopoietic stem-cell transplantation or who underwent chemotherapy and were treated with platelet transfusions. The results showed that patients suffered from severe bleeding despite transfusion.


Related Articles

  • Author Reply to... Robert Zimmermann, Jürgen Zingsem, Reinhold Eckstein, Jörg Mezger. Wandt, Hannes; Schäfer-Eckart, Kerstin; Greinacher, Andreas // Deutsches Aerzteblatt International;7/20/2015, Vol. 112 Issue 29/30, p506 

    The article offers information on several studies which reveals that the risk for hemorrhage varies between thrombocytopenia patients. Topics discussed include reduced risk of hemorrhage in autologous stem cell transplantation, intensive treatment of promyelocytic leukemia patients with platelet...

  • Effects of Exercise in Combination With Epoetin Alfa During High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma. Coleman, Elizabeth A.; Coon, Sharon K.; Kennedy, Robert L.; Lockhart, Kimberly D.; Stewart, Carol B.; Anaissie, Elias J.; Barlogie, Bart // Oncology Nursing Forum;May2008, Vol. 35 Issue 3, pE53 

    Purpose/Objectives: To determine the effect of aerobic and strength resistance training and epoetin alfa (EPO) therapy on transfusions, stem cell collections, transplantation recovery, and multiple myeloma treatment response.Design: Randomized clinical trial.Setting: A myeloma research and...

  • Patch: platelet transfusion in cerebral haemorrhage: study protocol for a multicentre, randomised, controlled trial. de Gans, Koen; de Haan, Rob J.; Charles B. Majoie; Maria M. Koopman; Brand, Anneke; Dijkgraaf, Marcel G.; Vermeulen, Marinus; Roos, Yvo B. // BMC Neurology;2010, Vol. 10, p19 

    Background: Patients suffering from intracerebral haemorrhage have a poor prognosis, especially if they are using antiplatelet therapy. Currently, no effective acute treatment option for intracerebral haemorrhage exists. Limiting the early growth of intracerebral haemorrhage volume which...

  • Platelet Transfusion and Hemorrhage. Zimmermann, Robert; Zingsem, Jürgen; Eckstein, Reinhold // Deutsches Aerzteblatt International;7/20/2015, Vol. 112 Issue 29/30, p505 

    The article offers information on several studies on relationship between platelet transfusion and hemorrhage. Topics discussed include bleeding hemorrhage in cases of therapeutic platelet transfusion, increased changes of intracerebral hemorrhage in acute myeloid leukemia (AML) patients,...

  • High-dose chemotherapy and breast cancer. Gradishar, William J.; Gradishar, W J // JAMA: Journal of the American Medical Association;10/13/99, Vol. 282 Issue 14, p1378 

    Reports on the questions being raised regarding the use of high-dose chemotherapy (HDC) and peripheral blood stem cell transplantation (PBSCT) as treatments for breast cancer. Possible errors made during the clinical trials of these two methods of treatment; Comparison between HDC and regular...

  • Increased requirement for platelet transfusions concurrent with enhanced bleeding during romiplostim treatment in a patient with thrombocytopenia due to bone marrow failure. Lotfi, Ramin; Moeller, Peter; Schmid, Mathias; Schrezenmeier, Hubert // Annals of Hematology;Nov2011, Vol. 90 Issue 11, p1357 

    A letter to the editor is presented which discusses a case of 46-year-old idiopathic thrombocytopenia (ITP) female patient which required platelet transfusion due to bone marrow failure and was administered with romiplostim treatment.

  • Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers. Giebel, S; Kruzel, T; Czerw, T; Sadus-Wojciechowska, M; Najda, J; Chmielowska, E; Grosicki, S; Jurczyszyn, A; Pasiarski, M; Nowara, E; Glowala-Kosinka, M; Chwieduk, A; Mitrus, I; Smagur, A; Holowiecki, J // Bone Marrow Transplantation;Jul2013, Vol. 48 Issue 7, p915 

    The optimal protocol for mobilization of hematopoietic stem cells in patients with lymphoid malignancies has not been determined so far. We retrospectively analyzed the efficacy and safety of Ara-C at a dose of 1.6 g/m2 compared with CY at a dose of 4.0 g/m2, both combined with filgrastim....

  • The Perils of Platelet Transfusions. Kruskall, Margot S. // New England Journal of Medicine;12/25/97, Vol. 337 Issue 26, p1914 

    Editorial. Focuses on the controversies surrounding platelet transfusions in reducing the risk of death from hemorrhage during chemotherapy for leukemia. Problem areas, including collection of platelet product by centrifugation or apheresis; Platelet storage; The lack of a reliable compatibility...

  • Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. Forrest, D L; Thompson, K; Dorcas, V G; Couban, S H; Pierce, R // Bone Marrow Transplantation;Jun2003, Vol. 31 Issue 12, p1143 

    Summary:We evaluated 40 patients undergoing high-dose chemo/radiotherapy (HDCT) and hematopoietic stem cell transplantation (HSCT) (allogeneic (22), autologous (18)) to determine the safety and feasibility of administering low molecular weight heparin (LMWH) as hepatic veno-occlusive disease...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics